REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE
The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
1 . A method of treating an autoimmune disease in a subject, comprising:
administering to the subject a therapeutically effective amount of a TAM receptor agonist comprising a phosphatidyl serine (PtdSer)-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane, thereby activating signaling from one or more TAM receptors, thereby treating the autoimmune disease.
2 . The method of claim 1 , wherein the autoimmune disease is selected from the group consisting of amyotriphic lateral sclerosis, celiac disease, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, inflammatory bowel disease (Crohn's disease and ulcerative colitis), Cushing's syndrome, Guillain-Barre syndrome, transverse myelitis, psoriasis, renal, pulmonary, and hepatic fibroses, Addison's disease, type I diabetes, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, Reiter's syndrome, and Grave's disease.
3 . The method of any of claims 1 - 2 , wherein the membrane is a liposome or a nanoparticle.
4 . The method of any of claims 1 - 3 , wherein the subject is a human.
5 . The method of any of claims 1 - 4 , wherein the TAM receptor is Axl, Mer and/or Tyro3.
6 . The method of any of claims 1 - 5 , wherein Gas6 and/or Protein S binds to the lipid membrane through the PtsdSer-Gla domain interaction.
7 . A composition comprising a PtdSer-containing membrane having a Gas6 and/or Protein S protein bound to said membrane.
8 . The composition of claim 7 , wherein the PtdSer containing membrane comprises a liposome or a nanoparticle.
9 . A method for classifying a virus as susceptible to anti-TAM therapy comprising:
i) determining whether the virus comprises PtdSer on the envelope surface; and/or
ii) determining whether the virus induces TAM signaling when in contact with a TAM ligand; and
iii) comparing a value for i) and/or ii) with a value for a virus with a known amount of PtdSer on the envelope surface and/or a virus known to induce TAM signaling, thereby classifying the virus as susceptible or resistant to anti-TAM therapy.
10 . The method of claim 9 , wherein the anti-TAM therapy is a small molecule inhibitor of TAM intracellular signaling.
11 . A method of identifying an agent that blocks virus infectivity comprising:
contacting one or more test agents with a virus and an immune cell; and
determining TAM receptor activation in the presence and absence of the test agent(s), wherein decreased TAM receptor activation in the presence of the test agent is indicative of an agent that blocks virus infectivity.
12 . A method of treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response with an agent disrupting the interaction between Gas6 and/or Protein S with PtdSer-containing lipid bilayer membranes.
13 . The method of claim 12 , wherein the pathological condition is a virus infection by an enveloped virus.
14 . The method of claim 12 or 13 , wherein the agent disrupting the interaction between Gas6 and/or Protein S with PtdSer is an antibody to the Gla-domain of Gas6 and/or Protein S.
15 . The method of claim 12 or 13 , wherein the agent disrupting the interaction between Gas6 and/or Protein S with PtdSer is a full length Gla-domain derived from human Gas6 or Protein S sequence, or a fragment thereof.
16 . The method of claim 12 or 13 , wherein the agent disrupting the interaction between Gas6 and/or Protein S with PtdSer is an antibody to PtdSer.
17 . The method of claim 12 or 13 , wherein the agent disrupting the interaction between Gash and/or Protein S with PtdSer is a natural or artificial peptide binding PtdSer.